» Articles » PMID: 31383026

Regulatory and Policy Tools to Address Unproven Stem Cell Interventions in Canada: the Need for Action

Overview
Journal BMC Med Ethics
Publisher Biomed Central
Specialty Medical Ethics
Date 2019 Aug 7
PMID 31383026
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The marketing of unproven direct-to-consumer stem cell interventions is becoming widespread in Canada. There is little evidence supporting their use and they have been associated with a range of harms. Canada has been slower to act against clinics offering these interventions than other jurisdictions, including the United States. Here, we outline the regulatory and policy tools available in Canada to address this growing problem.

Main Body: Health Canada's regulations governing cell therapies are complex, but recent statements make it clear that Health Canada believes it has jurisdiction over many of the currently marketed stem cell interventions. Still, further regulatory clarity is needed from Health Canada, as are increased directed enforcement efforts on interventions that fall within their scope. The Competition Bureau, via the Competition Act, prohibits advertisers from making materially false or misleading promotional representations. The Competition Bureau could collaborate with the scientific community to analyze the claims of existing clinics in Canada, and impose sanctions upon those who breach the established standard. Professional regulators, including provincial colleges of physicians and surgeons, have considerable power over what products and services their members can offer. Every college of physicians in Canada requires, via policy and codes of ethics, that doctors maintain evidence-based practices. This requirement is incompatible with offering many unproven stem cell interventions. Litigation may be another tool, including the use of fraud, misrepresentation and/or negligence claims for failing to meet the required standard of care. Finally, political pressure on federal and provincial lawmakers could encourage changes to marketing, cell therapy and professional regulations that would allow a more comprehensive response.

Conclusions: In sum, there are many existing tools that can be used to protect the public from unproven stem cell interventions. Increased bureaucratic will and grassroots efforts are needed in order to effect a positive policy response.

Citing Articles

Clinical use of autologous cell-based therapies in an evolving regulatory landscape: A survey of patient experiences and perceptions.

Ogbogu U, Case N F1000Res. 2024; 12:1165.

PMID: 39430869 PMC: 11489844. DOI: 10.12688/f1000research.141002.2.


The evolution and ongoing challenge of unproven cell-based interventions.

Brinsfield T, Pinson N, Levine A Stem Cells Transl Med. 2024; 13(9):851-858.

PMID: 39045646 PMC: 11386208. DOI: 10.1093/stcltm/szae050.


Ethical issues in direct-to-consumer healthcare: A scoping review.

Nagappan A, Kalokairinou L, Wexler A PLOS Digit Health. 2024; 3(2):e0000452.

PMID: 38349902 PMC: 10863864. DOI: 10.1371/journal.pdig.0000452.


Clinical, Histologic, and Transcriptomic Evaluation of Sequential Fat Grafting for Morphea: A Nonrandomized Controlled Trial.

Liu J, Wang J, Zhang Q, Lu F, Cai J JAMA Dermatol. 2024; 160(4):425-433.

PMID: 38324287 PMC: 11024779. DOI: 10.1001/jamadermatol.2023.5908.


Application of Platelet-Rich Plasma as a Stem Cell Treatment - an Attempt to Clarify a Common Public Misconception.

Fareez I, Liew F, Widera D, Mayeen N, Mawya J, Abu Kasim N Curr Mol Med. 2023; 24(6):689-701.

PMID: 37171013 DOI: 10.2174/1566524023666230511152646.


References
1.
Viswanathan S, Bubela T . Current practices and reform proposals for the regulation of advanced medicinal products in Canada. Regen Med. 2015; 10(5):647-63. DOI: 10.2217/rme.15.28. View

2.
Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S . Marketing of unproven stem cell-based interventions: A call to action. Sci Transl Med. 2017; 9(397). DOI: 10.1126/scitranslmed.aag0426. View

3.
Daley G . Polar Extremes in the Clinical Use of Stem Cells. N Engl J Med. 2017; 376(11):1075-1077. DOI: 10.1056/NEJMe1701379. View

4.
Sugarman J, Barker R, Kerridge I, Lysaght T, Pellegrini G, Sipp D . Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report. Stem Cell Reports. 2018; 11(5):1021-1025. PMC: 7206334. DOI: 10.1016/j.stemcr.2018.10.020. View

5.
Snyder J, Turner L, Crooks V . Crowdfunding for Unproven Stem Cell-Based Interventions. JAMA. 2018; 319(18):1935-1936. PMC: 6583473. DOI: 10.1001/jama.2018.3057. View